Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
BRAF Inhibitor (BRAFi)
100%
BRAF V600E
58%
Tumor
52%
ERK Pathway
50%
MEK Inhibitor (MEKi)
40%
Langerhans Cell Histiocytosis
31%
Mitogen-activated Protein Kinase
30%
Melanoma
29%
Cyclin-dependent Kinase 4 (CDK4)
27%
Resistance Mechanism
20%
Mutant BRAF
20%
Phosphoinositide 3-kinase (PI3K)
19%
Cancer Cells
18%
AKT Pathway
17%
Apoptosis Induction
16%
Extracellular Signal-regulated Kinase
16%
In Cancer
15%
Mesothelioma Cells
15%
Inhibitor Activity
15%
Cyclin-dependent Kinase 6 (CDK6)
15%
Dimerization
15%
Tumor Cells
15%
SHP2
15%
BCMA CAR-T
15%
Human Malignancies
15%
Signal Inhibition
15%
Mechanosignaling
15%
YAP Activation
15%
Therapeutic Strategies
15%
BRAF mutant
14%
Kinase Inhibitor
13%
Targeted Therapy
13%
Degrader
13%
RhoA
12%
Feedback Inhibition
12%
Therapy-resistant
10%
Kinase Inhibition
10%
Protomers
10%
Somatic mutation
10%
Tumor Regression
10%
Selective Inhibitor
10%
Wild-type KRAS
10%
Extracellular Signal-regulated Kinase Signaling
10%
Non-small Cell Lung Cancer (NSCLC)
10%
Dendritic Cells
10%
Helix C
9%
PLX4032
9%
Acquired Resistance
9%
V600E-BRAF
9%
Pharmacological Inhibitors
9%
Biochemistry, Genetics and Molecular Biology
Carcinogenesis
39%
Dimerization
31%
Mitogen-Activated Protein Kinase
30%
Protein Kinase B
25%
phosphorylation
25%
Langerhans Cell
23%
MEK Inhibitor
22%
Cancer Cell
21%
Kinase
20%
Phosphotransferase
20%
Product Inhibition
17%
Aromatic L-Amino Acid Decarboxylase
15%
Extracellular Signal-Regulated Kinases
15%
MAP2K1
14%
Vemurafenib
12%
Drive
11%
Rebound
11%
Cooperation
11%
Conformation
11%
Programmed Cell Death
10%
Protomer
10%
KRAS
10%
Somatic Mutation
10%
Phosphoinositide 3-Kinase
9%
Wild Type
9%
Proteomics
9%
Guanosine Triphosphate
9%
Tumor Suppressor Protein
9%
Targeted Therapy
9%
Signal Transduction
8%
Drug Resistance
8%
Autoinhibition
7%
Allosteric Site
7%
RNA Splicing
7%
Janus Kinase 1
7%
Mechanistic Target of Rapamycin
7%
Sodium-Hydrogen Antiporter
7%
Protein Kinase C
7%
Cystic Fibrosis Transmembrane Conductance Regulator
7%
Developmental Stage
7%
Mediterranean Fruit Fly
7%
ROCK1
7%
Fibrinogen
7%
Transcription
7%
Phosphatase
7%
Cell Membrane Potential
7%
Cell Proliferation
7%
Immune Checkpoint Inhibitor
7%
Immune Response
7%
Zalcitabine
7%
Medicine and Dentistry
Mitogen-Activated Protein Kinase
62%
Melanoma
30%
MEK Inhibitor
21%
Cancer
17%
Combination Therapy
16%
Carcinogenesis
15%
Langerhans Cell Histiocytosis
15%
Cancer Cell
15%
CAR T-cell therapy
15%
Multiple Myeloma
15%
B Cell Maturation Antigen
15%
Phosphotransferase
14%
Tumor
12%
Tumor Regression
11%
Non Small Cell Lung Cancer
11%
Targeted Therapy
10%
Cancer Therapy
10%
Tumor Cell
10%
Immune Response
9%
Dendritic Cell
8%
Juvenile Xanthogranuloma
8%
Immune Checkpoint Inhibitor
8%
Personalized Medicine
7%
Protein Kinase B
7%
Xenograft
7%
Somatic Mutation
7%
Oncology
7%
MAPK1
7%
Cell Migration
7%
Vemurafenib
7%
Mitogen Activated Protein Kinase 1
7%
Hematology
7%
Melanoma Skin Cancer
7%
Therapy Resistance
7%
Paralogy
7%
Pathogenesis
7%
Protein P53
7%
Cell Proliferation
7%
Biological Marker
7%
Immunotherapy
7%
Capmatinib
5%
Neoplasm
5%
Protein Kinases
5%
Guanine Nucleotide
5%
Diseases
5%